Krystal Biotech KRYS
$308.89 −$6.93 (-2.19%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $308.85 -0.01%
Open$313.38
Prev close$315.82
Day range$308.22 – $321.27
Volume286.7K
Market cap$9.15B
P/E (TTM)42.0
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$127.34M+30.2% YoY
Operating profit$71.15M+72.0% YoY
Net profit$63.07M-20.5% YoY
Diluted EPS$2.05-22.9% YoY
Free cash flow$90.25M+137.8% YoY
Operating cash flow$91.25M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Gross margin94.3%
Operating margin48.4%
Net margin47.9%
Return on equity17.5%
Return on assets15.9%
Return on invested capital15.3%
Current ratio7.89
Liabilities / assets9.5%
Cash & investments$911.85M
Total debt$6.77M
Net cash (debt)$905.08M
Free cash flow / sales66.0%
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Revenue as Reported | $127.34M | $119.22M | $116.36M | $389.13M | $107.11M |
| Total Operating Revenue | $127.34M | $119.22M | $116.36M | $389.13M | $107.11M |
| Cost of Revenue | $7.56M | $6.44M | $6.32M | $23.05M | $6.59M |
| Gross Profit | $119.79M | $112.79M | $110.03M | $366.08M | $100.51M |
| Operating Expense | $48.64M | $54.37M | $56.35M | $204.79M | $56.24M |
| Selling and Admin Expenses | $33.75M | $39.85M | $41.01M | $146.74M | $41.45M |
| Research & Development | $14.89M | $14.52M | $15.33M | $58.05M | $14.79M |
| Operating Profit | $71.15M | $58.42M | $53.69M | $161.30M | $44.27M |
| Net Non-Operating Interest Income (Expense) | $9.00M | $7.66M | $7.75M | $28.18M | $6.86M |
| Non-Operating Interest Income | $9.00M | $7.66M | – | $28.18M | $6.86M |
| Pretax Profit | $80.15M | $66.08M | $61.44M | $189.47M | $51.13M |
| Tax | $17.08M | $11.31M | $5.51M | -$15.36M | -$269,000.00 |
| Net Profit | $63.07M | $54.77M | $55.93M | $204.83M | $51.40M |
| Profit from Continuing Operations | $63.07M | $54.77M | $55.93M | $204.83M | $51.40M |
| Net Income to Parent Company | $63.07M | $54.77M | $55.93M | $204.83M | $51.40M |
| Net Income to Common Stockholders | $63.07M | $54.77M | $55.93M | $204.83M | $51.40M |
| Basic EPS | $2.13 | $1.85 | $1.91 | $7.08 | $1.77 |
| Diluted EPS | $2.05 | $1.79 | $1.83 | $6.84 | $1.70 |
| Total Other Finance Costs | – | – | -$7.75M | – | – |
| Special Income (Charges) | – | – | – | $0.00 | $0.00 |
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Assets | $1.59B | $1.50B | $1.40B | $1.33B | $1.33B |
| Total Current Assets | $1.12B | $1.06B | $1.02B | $1.02B | $1.02B |
| Cash and Cash Equivalents & Short-Term Investments | $911.85M | $845.63M | $823.41M | $827.79M | $827.79M |
| -Cash and Cash Equivalents | $462.84M | $427.74M | $501.31M | $496.30M | $496.30M |
| -Short Term Investments | $449.01M | $417.89M | $322.09M | $331.49M | $331.49M |
| Receivables | $133.12M | $138.66M | $127.02M | $127.43M | $127.43M |
| -Accounts Receivable | $133.12M | $138.66M | $127.02M | $127.43M | $127.43M |
| Prepaid Assets | $8.54M | $15.31M | $10.64M | $14.01M | $14.01M |
| Inventory | $50.79M | $45.56M | $42.65M | $40.48M | $40.48M |
| Other Current Assets | $17.47M | $14.49M | $16.03M | $14.91M | $14.91M |
| Total Non-Current Assets | $464.29M | $441.00M | $377.23M | $309.19M | $309.19M |
| Net PPE | $158.90M | $160.60M | $160.62M | $158.02M | $158.02M |
| -Gross PPE | $197.97M | $196.97M | $194.39M | $189.30M | $189.30M |
| -Accumulated Depreciation | -$39.07M | -$36.37M | -$33.77M | -$31.28M | -$31.28M |
| Investments and Advances | $282.30M | $257.29M | $193.49M | $128.07M | $128.07M |
| -Available for Sale Securities | $282.30M | $257.29M | $193.49M | $128.07M | $128.07M |
| Non-Current Deferred Assets | $22.82M | $22.82M | $22.82M | $22.82M | $22.82M |
| Other Non-Current Assets | $269,000.00 | $284,000.00 | $300,000.00 | $287,000.00 | $287,000.00 |
| Total Liabilities | $150.47M | $141.52M | $120.24M | $114.23M | $114.23M |
| Total Current Liabilities | $142.14M | $127.40M | $107.80M | $102.94M | $102.94M |
| Payables | $23.60M | $21.35M | $17.20M | $14.16M | $14.16M |
| -Accounts Payable | $6.73M | $6.54M | $4.09M | $3.24M | $3.24M |
| -Total Tax Payable | $16.87M | $14.81M | $13.11M | $10.92M | $10.92M |
| Current Accrued Expenses | $112.40M | $100.81M | $85.63M | $83.44M | $83.44M |
| Short-Term Debt and Capital Lease Obligation | $1.82M | $1.81M | $1.80M | $1.77M | $1.77M |
| -Current Capital Lease Obligation | $1.82M | $1.81M | $1.80M | $1.77M | $1.77M |
| Other Current Liabilities | $4.33M | $3.43M | $3.18M | $3.58M | $3.58M |
| Total Non-Current Liabilities | $8.33M | $14.13M | $12.44M | $11.29M | $11.29M |
| Long Term Debt and Capital Lease Obligation | $6.77M | $7.05M | $7.31M | $7.57M | $7.57M |
| -Long Term Capital Lease Obligation | $6.77M | $7.05M | $7.31M | $7.57M | $7.57M |
| Other Non-Current Liabilities | $1.56M | $7.08M | $5.12M | $3.72M | $3.72M |
| Total Equity | $1.44B | $1.36B | $1.28B | $1.22B | $1.22B |
| Stockholders' Equity | $1.44B | $1.36B | $1.28B | $1.22B | $1.22B |
| Capital Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| -Common Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Additional Paid-In Capital | $1.25B | $1.23B | $1.20B | $1.19B | $1.19B |
| Retained Earnings | $197.93M | $134.86M | $80.10M | $24.16M | $24.16M |
| Gains/Losses Not Affecting Retained Earnings | -$9.24M | -$4.34M | -$1.62M | $1.14M | $1.14M |
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Operating Cash Flow | $91.25M | $74.79M | $80.38M | $200.87M | $77.51M |
| Net cash flow from continuing operations | $91.25M | $74.79M | $80.38M | $200.87M | $77.51M |
| Net Income from Continuing Operations | $63.07M | $54.77M | $55.93M | $204.83M | $51.40M |
| Gain/Loss from Continuing Operations | -$475,000.00 | -$748,000.00 | -$529,000.00 | -$5.95M | -$404,000.00 |
| Depreciation & Depletion & Amortization | $1.69M | $1.57M | $1.73M | $6.55M | $1.76M |
| Other Non-Cash Items | -$490,000.00 | $174,000.00 | $136,000.00 | $684,000.00 | $289,000.00 |
| Change in Working Capital | $14.29M | $5.62M | $10.08M | -$36.42M | $9.50M |
| -Change in Receivables | $5.43M | -$11.97M | $58,000.00 | -$22.12M | $2.49M |
| -Change in Inventory | -$2.00M | -$958,000.00 | -$243,000.00 | -$6.29M | -$1.06M |
| -Change in Prepaid Assets | $2.99M | -$4.86M | $1.67M | -$14.66M | -$245,000.00 |
| -Change in Payables and Accrued Expense | $8.35M | $21.64M | $7.40M | $4.95M | $7.91M |
| -Change in Other Current Liabilities | -$470,000.00 | $1.77M | $1.21M | $1.70M | $397,000.00 |
| Net cash flow from investing | -$57.98M | -$161.58M | -$63.58M | -$58.42M | $11.16M |
| Net Cash Flow from Continuing Investing Activities | -$57.98M | -$161.58M | -$63.58M | -$58.42M | $11.16M |
| Net PPE Purchase and Sale | -$996,000.00 | -$3.57M | -$7.15M | -$11.95M | -$2.14M |
| Net Investment Purchase and Sale | -$56.99M | -$158.02M | -$56.44M | -$46.90M | $13.30M |
| Financing Cash Flow | $3.41M | $15.05M | -$10.46M | $8.71M | $15.67M |
| Net Cash Flow from Continuing Financing Activities | $3.41M | $15.05M | -$10.46M | $8.71M | $15.67M |
| Proceeds from Stock Option Exercised | $3.42M | $15.16M | $6.50M | $22.66M | $15.69M |
| Net Other Financing Charges | -$11,000.00 | -$108,000.00 | -$16.96M | -$13.96M | -$23,000.00 |
| Ending Cash Balance | $462.84M | $427.74M | $501.31M | $496.30M | $496.30M |
| Net Change in Cash | $36.68M | -$71.74M | $6.34M | $151.15M | $104.34M |
| Beginning Cash Balance | $427.74M | $501.31M | $496.30M | $344.87M | $392.60M |
| Effect of Exchange Rate Changes | -$1.58M | -$1.83M | -$1.33M | $286,000.00 | -$637,000.00 |
| Free Cash Flow | $90.25M | $71.22M | $73.23M | $188.91M | $75.37M |
| Deferred Tax | – | – | – | -$22.85M | $1.84M |
| Net Other Investing Changes | – | – | – | $435,000.00 | $0.00 |
| Net Common Stock Issuance | – | – | – | $0.00 | – |
No comments yet — be the first to weigh in on KRYS.
Sign in to join the discussion.